Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
View/Download PDF

Translate this page into:

Review Article
155 (
1
); 11-21
doi:
10.4103/ijmr.IJMR_808_18

Urinary immunoglobulins in viral diagnosis: An overview

Maximum Containment Facility, ICMR- National Institute of Virology, Pune, Maharashtra, India
Entomology Division, ICMR- National Institute of Virology, Pune, Maharashtra, India
ICMR-Chair for Virology & Zoonoses, ICMR- National Institute of Virology, Pune, Maharashtra, India

For correspondence: Dr Devendra T. Mourya, National Institute of Virology, 20-A, Dr Ambedkar Road, Pune 411 001, Maharashtra, India e-mail: dtmourya@gmail.com

Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Antibody detection by serological methods gained a lot of interest in recent years and has become the backbone of virological diagnosis. Despite the detection of all five classes of immunoglobulins in urine, not much attention has been paid to the use of urine as a diagnostic sample to detect viral antibodies. Unlike venipuncture, this non-invasive mode of sample collection can help cover all age groups, especially paediatric and old age patients, where blood collection is difficult. Using urine as a sample is also economical and involves lesser risk in sample collection. The antibodies are found to be stable in urine at room temperature for a prolonged period, which makes the sample transport management easier as well. A few recent studies, have also shown that the detection limit of antibodies in urine is at par with serum or other clinical material. So, the ease in sample collection, availability of samples in large quantity and stability of immunoglobulins in urine for prolonged periods can make urine an ideal sample for viral diagnosis.

Keywords

Antibody detection
diagnostics
immunoglobulins
urine
viral diseases

Introduction

Antibody detection has become a valuable tool in viral diagnostics and is accomplished by several serological techniques viz. complement fixation, neutralization test, haemagglutination inhibition, ELISA (Enzyme Linked Immunosorbent Assay), etc. All of these techniques are well established in virology laboratories and have been the backbone of diagnostic virology since before the advent of molecular tools12. Despite the availability of newer molecular techniques, serological techniques still remain the mainstay of viral diagnosis in many laboratories due to their specificity and economy for mass screening. Serological techniques have played an important role in the diagnosis of aetiological agents during the emergence and re-emergence of several diseases of viral origin globally in the past two decades34. Advancements in the techniques over the years have made many of these rapid and sensitive2 with most of these tests available in a ready-to-use kit format5. This has improved the efficiency of diagnoses that lead to the proper management and control of viral outbreaks.

The utility of urinary antibodies as a diagnostic tool has been investigated for certain viral diseases due to the inexpensive and non-invasive nature of sample collection67. During viral or bacterial infections, antibodies to immunoglobulins are excreted through urine, which have been found to be stable for considerable periods (Table I)89101112. The antibodies can be detected in urine using class-specific assays or Western blot13. The use of urine for antibody detection also reduces the risks involved in sample collection and large quantities could be collected from all age groups, especially paediatric patients and elderly people where blood collection is relatively difficult. The present review focuses on the available literature, advantages and limitations of using urine as a diagnostic sample for the detection of viral immunoglobulins.

Table I Stability of urinary immunoglobulins against viral pathogens
Temperature Virus and type of Igs Stability status
Room temperature HIV-1, IgG Stable for 55 days8
Rubella, IgG For five months at 25°C with 0.1% sodium azide9
HCV, IgG Stable for 20 days10
At 4°C HIV-1, IgG Stable for one year at 2°C-8°C8
Rubella, IgG Stable for five months with 0.1% sodium azide9
HAV, IgM Stable for 48-72 h11
HAV, IgM Stable for five months12
At 20°C and below HAV, IgM Significant reduction in titre (to 81.25% and 76.08% after three and six months, respectively, when stored at −70°C) 11
HAV IgM Stable for six months at −70°C12
HCV Stable at −25°C and −80°C for longer periods10

HCV, hepatitis C virus; HAV, hepatitis A virus; Ig, immunoglobulin

Presence of viral antibodies in urine

Lerner et al14 were the first to report the presence of viral antibodies in human urine when they observed neutralizing antibodies (NAbs) to poliovirus in patient’s urine. The investigators also demonstrated positive association of NAbs in urine with that of serum. In the same year, Ashkenazi and Melnick15 demonstrated the presence of NAbs to SV40 (simian virus) in urine samples of experimentally inoculated monkeys, which appeared with the waning of viruria. Similarly, another group in 1969 observed SV40 Nabs in urine and correlated it with high titre in the serum16. Subsequently, antibodies, either alone or in combination with several viruses were detected in patient’s urine. Table II14151617181920212223242526272829303132333435363738394041 depicts the different viral antibodies detected in urine.

Table II Urinary antibodies against viral pathogens
Name of virus Family Symptoms Antibody type detected in urine Test and antigen used for detection
Poliovirus 1, 3 Picornaviridae Fever, fatigue, headache, vomiting, stiffness of the neck, pain in the limbs, paralysis of limbs nAb14, IgA17 Plaque reduction combined with immunoinactivation, using the whole virus14, RIA using purified polio virus17
BK virus Polyomaviridae Renal dysfunction (post-transplant cases)18 IgG19 Haemagglutination inhibition tests using supernatant fluid/W138 cells infected with BKV as antigen19
SV 40 Polyomaviridae Viral antigen detected in human brain tumours, mesotheliomas, osteosarcomas20 nAb1516 Neutralization test using infected green monkey cells culture supernatant as antigen15, neutralization test16
Adeno virus Adenoviridae In chimpanzees with chronic adenoviral viruria21 nAb, IgG, IgA21 Neutralization test and immunofluorescence using virus infected WI-38 cell cultures21
Bovine leukemia virus Retroviridae Bovine leucosis in cattle22 IgG22 Commercial ELISA kit
Dengue virus Flaviviridae Nausea, vomiting, pain behind eyes, muscle pain, joint pain, rashes, bleeding23 IgA6723, IgG23 Commercial Ig A kit against Dengue virus6, AACELISA and GAC-ELISA using tetravalent dengue virus antigen prepared in suckling mice brain and extracted by acetone–sucrose723
Hepatitis A Picornaviridae Fever, nausea, lack of appetite, diarrhoea, dark-coloured urine, jaundice24 IgG2512 IgM monomer2512 Tissue culture grown antigen25, RIA using tissue culture-derived HAV Ag12
Hepatitis B Hepadnaviridae Fatigue, nausea, vomiting, abdominal pain, jaundice, dark urine, cirrhosis/liver cancer (in some cases)26 IgG (Anti-HBc), IgM monomer2512 RIA using recombinant HBcAg (gifted)25, RIA using liver-derived HBcAg12
Hepatitis C Flaviviridae 80% asymptomatic, fever, fatigue, vomiting, nausea, abdominal pain, dark coloured urine, grey-coloured faeces, joint pain and jaundice27 IgG10 Commercial ELISA
HIV-1 Retroviridae Progressive immunosuppression and secondary infections28 IgG (antibodies against gp120, gp160, p17, p24, p33, gp41, p51, p55 and p61)28 Commercial ELISA
Rubella Togaviridae Rash, low fever, nausea, conjunctivitis swollen lymph glands, arthritis and painful joints (adults), congenital rubella syndrome29 IgA29, IgG929 ELISA using commercially available rubella viral antigen29, commercial ELISA9
Hepatitis E Hepeviridae Fever, anorexia, nausea, vomiting, jaundice30 IgG, IgA31 ELISA using recombinant ORF2 protein of HEV31
HCMV Herpesviridae In immunosuppressed individuals causes retinitis, oesophagitis, encephalitis, myelitis, radiculopathy, colitis32 IgA, IgG33 ELISA using CMV complement fixing antigen33
Hantavirus Bunyaviridae Headache, abdominal pain, fever, chills, nausea, blurred vision, rash, kidney failure34 IgA, IgG35 TR-FRET using baculovirus-expressed–N PUUV, immunofluorescence using PUUV infected acetone-fixed Vero E635
H1N1 Orthomyxoviridae Fever, chills, sore throat, cough, headache, coryza, myalgia, prostration36 IgG37 Purified haemagglutinin from influenza A/Taiwan (H1N1)37
RSV Paramyxoviridae Fever, cough, sore throat, shortness of breath, coryza38 IgG37 RSV CF antigen37
Zika virus Flaviviridae Fever, headache, rash, joint pain, muscle pain, conjunctivitis (red eyes)39 IgM39 Detected using whole genome-fragment phage display libraries with binding to antigenic sites in E, NS3 and NS539
HPV Papillomaviridae Cervical carcinoma IgM, IgG, IgA40 Using HPV-L1-fusion protein antigens in a glutathione S-transferase multiplex assay40 and virus-like particle-based ELISA41 to detect HPV-6, -11, -16 and-18

HCMV, human cytomegalovirus; HPV, human papilloma virus; nAb, neutralizing antibodies; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; RIA, radioimmunoassay; HAV Ag, hepatitis A virus antigen; HEV, hepatitis E virus; CMV, cytomegalovirus; TR-FRET, time-resolved forster resonance energy transfer; PUUV, puumala orthohantavirus; RSV, respiratory syncytial virus; CF, cystic fibrosis; ELISA, enzyme-linked immunoassay; GAC-ELISA, IgG antibody capture ELISA; ORF2, isoform capsid protein; AACELISA, IgA antibody capture ELISA

Concentration and stability of antibodies in urine

Concentration and stability of antibodies are important while considering a sample for its diagnostic potential. In comparison to serum, concentration of viral antibodies in urine is low4243. It depends on many factors viz., fluid intake, use of diuretics, body posture at the time of collection, physical activity etc2543. The concentration can be optimized for tests either by using undiluted samples or by increasing sample volume. Other methods such as concentrating the sample or extension of the incubation time, etc. can also be employed4344. High concentration of urine has been found to increase sensitivity in many assays where the total IgG concentration required for saturating the binding sites was optimal45.

Immunoglobulins are found to be stable in urine for a prolonged period; however, fresh urine or samples stored for a short duration at 4°C are ideal for diagnosis42. In a study on the stability of urinary proteins under various conditions, it was found that IgG was stable at room temperature for seven days and at 4°C for a month with and without preservatives, whereas the IgG concentration was found to decrease upon storage at −20°C without preservative46. Several viral antibodies have been reported to be stable at ambient temperature, 4°C, −20°C and −80°C conditions for varying periods (Table I). Repeated freeze-thawing of urine has, however, shown a reduction in antibody titres4647. On the contrary, freeze-thawing had no effect on the stability of Hepatitis C virus antibodies in one study10. Tencer et al46 have demonstrated the use of benzamidinium chloride, EDTA (ethylenediamine - tetraacetic acid), tris (hydroxymethyl)-aminomethane azide, etc. for successful preservation for varying periods of storage. Thimerosal (5 mg/ml) has also been used as a preservative and stability of HIV-1 antibodies for six months at −20°C has been demonstrated with this preservative43. Sodium azide at a final concentration of 0.1 per cent was also used as a preservative and found antibodies to be stable at room temperature and 4°C9.

Origin of urinary immunoglobulins

A urine proteome analysis reportedly showed >1500 different proteins48. These proteins were evenly distributed in urine as compared to other body fluids. A healthy person excretes ~150 mg protein through urine in a day and more than half of which is contributed by glomerular filtration of blood49. Healthy individuals can excrete 1.1 mg of IgA and ~3 mg of IgG during a 24 h period50. Due to its larger size, IgM is not filtered through kidneys; however, monomeric forms have been detected in urine51.

Immunoglobulins reach urine either through glomerular apparatus or by the local synthesis in the urinary tract. Glomerular apparatus comprises endothelial lining, basement membrane and podocytes that play a major role in filtration, and injury to any of these layers can alter the balance of filtration52. It largely depends on the molecular size, shape, charge of solute, concentration in serum and renal function53. The glycosialoprotein coating of the endothelium imparts a negative charge to the glomerular membrane and this explains how the negatively charged plasma proteins are retained in circulation. The small percentage of immunoglobulins, which manage to enter the filtrate, are reabsorbed by the tubule and catabolized. Immunoglobulin filtration from blood circulation to urine was experimentally proven by intravenous injection of radio-labeled human gamma globulin and its recovery in the urinary globulin fraction54. The FcRn receptor, which is expressed on the podocytes and the proximal convoluted tubule, aids in IgG transport across the membrane, which may be the reason why antibodies are not found in many infections55.

Glomerular permeability, in general, could be altered by glomerulonephritis, endothelial cell damage, immune complex deposition in the glomerular basement membrane, podocyte effacement and nephritic syndrome515657. Deposition of macromolecules, which happen to escape the endothelial lining and basement membrane, can damage the podocyte. The glomerular damage could be either due to direct infection by viruses or by the inflammatory cytokines released during infection. This has been experimentally shown with HIV-1 and other viruses, viz., Parvovirus B19, SV 40, cytomegalovirus (CMV), Epstein–Barr virus, etc., which have probable association with glomerulosclerosis58. Dengue virus NS1 antigen is known to damage the glycocalyx layer as demonstrated by the increased heparin sulphate excretion, a component of glycocalyx layer in urine of children with severe dengue infection59. Antibody excretion seen in Hantaan virus cases with haemorrhagic fever and renal syndrome stopped when the normal kidney function was restored34. The absence of urinary dysfunction with the detection of IgG from cattle urine was observed in Bovine Leukaemia virus infection, indicating the origin to be serum22.

The concept of local IgG synthesis has been confirmed in studies showing urinary immunoglobulins in children with pyelonephritis or urinary tract infections60 as well as in experimentally infected laboratory animals6162. Secretory IgA antibody has been isolated from urine50. IgA- and IgM-positive plasma cells were found in the bladder urothelium in urinary bladder infections, which is an important part of the mucosal immune system63. Intact immunoglobulin without albuminuria has been reported in the urine of HIV patients64. The ability of renal epithelial cells to act as a reservoir has been studied extensively in HIV infections and compartmentalized immune response was observed in such patients65. Urnovitz et al8 analyzed various urinary antibody tests for HIV-1 and hypothesized that the above could be the reason for the urine positive seronegative cases and positivity of urinary IgA in most of the cases strengthen its local origin. The theory of local immune response contributing to antibody production was also suggested in congenital CMV infection by demonstrating CMV specific-secretory IgA in urine of infants66. The passive transfer may also cause urine positivity of CMV as it was observed in the urine of the uninfected34. Haemorrhages to the urinary tract can also contribute to the presence of antibodies in urine. Bleeding into the urinary tract can also result in antibodies in urine, as shown in individuals with schistosomiasis67.

Viral nephropathy

Viral infections are known to cause kidney damage. Viruses, viz., HIV, HBV, HAV, HCV, Epstein–Barr virus, Parvovirus B19, Hantavirus, SARS-CoV, BK virus and Influenza A virus etc., have shown a direct association with kidney diseases. Dengue, CMV, adeno and Coxsackie B virus have also been found to cause nephropathy6869. A suppositious role has also been attributed to viruses such as mumps, measles, varicella and herpes68. Varying degrees of proteinuria have been reported from many of these infections. The mechanisms attributed to virus-related kidney injury have a direct cytopathic effect on glomerular/tubular epithelial cells, inflammatory response to infection by host, injury due to immune complex deposition, therapeutic nephrotoxicity and multi-organ failure69.

HIV and hepatitis viruses are well studied among the viruses that induce kidney diseases. HIV-associated nephropathy is well established and a wide range of lesions are reported from patients7071. Compartmentalized viral replication has been observed in kidneys70. Focal segmental glomerulosclerosis and immune complex-mediated glomerulonephritides are also reported from HIV patients71. Renal toxicity has been observed with many antiretroviral agents, which cause damage to the filtration barrier72. HBV causes glomerulonephropathy and viral antigen depositions have been demonstrated in the glomeruli73. Secondary glomerular disease in the form of membraneous/IgA nephropathy, immune complex-related vasculitis and complement-mediated injury has also been reported with HBV infection74. HCV infection inflicts kidney damage by direct renal invasion or by circulating cryoglobulins causing mesangiocapillary glomerulonephritis75. Incidences of acute tubular necrosis, interstitial nephritis and glomerulonephritis have been reported in HAV patients76. Glomerulonephritis has also been observed in patients with HIV and HCV coinfection77.

Urine-based diagnostic assays

ELISA and Western blot-based assays were used initially to detect urinary antibodies. The United States Food and Drug Administration licensed an enzyme immunoassay and Western blot for the detection of HIV-1 antibodies in urine in 201913. Advancements in urine-based diagnostics have led to the development of recombinant/synthetic antigen-based assays843. Many researchers employed specific immunoglobulin capture assays for urinary antibody detection, which showed promising results with good accuracy. The assays along with their reported sensitivity and specificity are enlisted in Table III78798081828384.

Table III Accuracy of assays employed to detect urinary antibodies against viral pathogens
Virus Method of detection Antigen used for detection Sensitivity (%) Specificity (%) Reference
HIV-1 EIA Commercial assay 98 99.8 64
EIA Commercial assay 89.6 97.3 78
Rapid assay Recombinant env proteins 97.89 100 79
GACPAT Commercial antigen 100 97-99 42
GACELISA Recombinant HIV env-gag construct antigen 99.4 97-99 42
GACPAT Commercial HIV antigen 96.5 98.8 80
GACELISA 98.8 99.2
Immunocomplex transfer enzyme immunoassay (rRT antigen) rRT 100 100 40
Western blot Commercial assay 97.2 100 39
98.6 100
EIA Commercial assay 99.5 98.3 81
EIA Commercial assay 100 88.8 82
Western blot Commercial antigen 97.7 100 83
HCV ELISA Commercial ELISA and immunoblot 100 100 84
HAV GACRIA Tissue culture grown antigen 98.9 99.1 25
MACRIA Tissue culture grown antigen 95.8 99.6 25
ELISA - 88.98 92.92 12
IgM capture ELISA Cell culture grown virus antigen 95.65 100 11
IgG capture ELISA 97.76 76.47
IgA capture ELISA 92.23 88.18
HBV GACRIA Recombinant HBcAg 94.2 100 25
MACRIA Recombinant HBcAg 26.19 100 25
Rubella ELISA, HI Commercial assay 96 99 9
ELISA Commercial RV antigen 100 100 29
Dengue Rapid diagnostic test (IgG, IgA) in house ELISA (IgG, IgA) Commercial assay 27.9 100 7
10.7
40.1
GACELISA Antigen prepared in mouse brains 100 100 23
EIM 61
HCMV ELISA pp150 expressed in Escherichia coli 70 94 66
ELISA (IgA) Complement fixing antigen 38.88 92 33
ELISA (IgG) 76.9 50

IgG, immunoglobulin G; IgM, immunoglobulin M; IgA, immunoglobulin A; EIA, enzyme immunoassay; GACPAT, IgG antibody capture particle-adherence test; ELISA, enzyme-linked immunoassay; GACELISA, IgG antibody capture ELISA; GACRIA, IgG antibody capture radioimmunoassay; MACRIA, immunoglobulin M capture radioimmunoassay; HCV, hepatitis C virus; HAV, hepatitis A virus; HBV, hepatitis B virus; HCMV, human cytomegalovirus; rRT, recombinant reverse transcriptase; RV, rotavirus; HBcAg, hepatitis B core antigen; HI, haemagglutination inhibition

Effect of pH in urine samples

The pH variations in urine samples are wide as compared to serum samples creating a major hurdle in the validation of diagnostics. The studies that attempted to uncover the effect of pH variation on some assays have shown contradictory results104385. No significant effect on the absorbance value of ELISA could be detected by variations in the pH range 5 to 7.51085. However, Hashida et al43 saw a reduction in immune complex transfer enzyme immunoassay signals in the acidic pH range and observed maximum signals at pH 7.0-8.0.

Antibody kinetics in urine

Although most of the studies on urine-based diagnostic assays were restricted mainly to antibody detection, a few tried to understand the antibody kinetics in either diseased patients or in vaccinated individuals.

Comparison with the serum concentration was presumably helpful in deciding the window period for diagnosis. Connell and Parry86 demonstrated the simultaneous appearance of urinary and serum antibodies against p24 and gpl60 antigens in HIV patients. Uropositivity in the convalescent phase in paired serum samples by MAC (IgM antibody capture) ELISA has been demonstrated in hepatitis A patients11. Conversely, Rodríguez Lay Lde et al12 found a faster degradation of urinary IgM compared to serum in six months in the case of HAV infection. However, the investigators observed higher IgM levels in urine than serum in seven patients at the initial phase of the disease. Zhang et al10 reported a good correlation of anti-HCV (against NS4, NS5, Core 1, 2, 3, 4) detection between serum and urine samples obtained from forensic autopsy cases. Contradictory results were published against the study by Elsana et al87, and the probability of mixing of serum and urine in autopsy cases was cited as a drawback in the earlier study.

Vazquez et al23 have demonstrated the kinetics of urinary IgA and IgG antibodies in comparison to serum antibodies to classify primary and secondary dengue infections. Although no IgM antibody could be detected in urine, IgG antibodies were detected between 3 to 7 days of onset in secondary infections using an in-house antibody capture ELISA (using an antigen mixture of the four dengue serotypes). Zhao et al6 have shown that urinary IgA antibodies detected by a rapid test could be a good marker to determine secondary dengue infections and can be used as a warning signal for clinical management in severe dengue cases. A similar pattern of serum and urinary IgG antibody levels were observed in the initial two weeks of the study in dengue patients, but the latter started decreasing in the following weeks and only 10 per cent showed positivity after three months, while the plasma IgG remained stable7. Their analysis suggested that the urinary concentration of antibody depends on the patient’s immune status and sampling time. With respiratory syncytial virus and H1N1 virus, a significant rise in antibody titre against RSV CF antigen or purified haemagglutinin from influenza A/Taiwan (H1N1) was observed between acute and convalescent urine samples by GAC (IgG antibody capture) ELISA37. However, low concentration of IgG and IgA antibodies against ORF 2 (open reading frame 2) protein was observed in hepatitis E patients, indicating either an undisturbed renal function or inadequacy of urine samples for diagnosis31. Urinary IgG antibody titre showed an increasing trend from 3rd/4th wk to 28th wk like that of serum IgG antibodies in a rubella virus vaccine-induced infection study depicting the application of this non-invasive approach for screening young children9.

The study also observed that anti-Rubella virus IgA/IgG ratio in urine could be a useful marker in diagnosing recent infection.

Limitations

Low concentrations of antibodies and limited knowledge on the antibody kinetics/ stability at different physiological conditions are the major limitations in using urine as a diagnostic sample. In addition, the presence of chemicals or drug residues in urine, changes in pH, differences in urine matrix components among individuals, etc. can also influence immunoassay results4388. The persistence of IgM antibodies in virus carriers can make it difficult to interpretate the results though it can be managed by relating the IgG and IgM values. Demonstration of a significant increase in antibody titre between acute and convalescent samples require quantification of total immunoglobulin37. Even with recommended ELISA and Western blot kits for anti-HIV-1 antibody detection in urine, indeterminate results (values) due to the presence of autoimmune self-antigens are a major concern. The complexing of antigens with specific antibodies can also interfere with immunoassays and this should be kept in mind while using urine as a diagnostic sample.

Conclusions

Overall, diagnostic tools can be useful in public health if they are specific, sensitive, cost-effective and user-friendly. Urine may find application as a useful diagnostic sample for the detection of antibodies due to its unique advantages in comparison with invasive procedures. Its potential as a diagnostic sample has not been fully explored so far due to low concentration of antibodies, variations in results due to physiological changes, methods of collection, presence of drug residues and other chemicals, etc. However, recent studies have shown the application of urine for antibody detection in many diseases. Urine-based diagnostic assays like specific immunoglobulin capture assays have shown good accuracy at par with serological assays. Most of the investigations reported are on a limited number of samples, which necessitates large-scale studies to explore the potential of urine as a diagnostic sample. Moreover, the detection of antibodies in urine has given new insights into the pathogenesis of HIV infections which points to the potential application of this approach for other microbes also. Screening of urine for antibodies in cases of viruses that are known or suspected to cause nephropathy should also be considered. Little is known about the quantity, site of synthesis and function of virus-specific urinary immunoglobulins. Studies are hence needed to understand the antibody kinetics of different viruses, particularly of public health importance where the urine samples can be used.

Financial support & sponsorship: None.

Conflicts of Interest: None.

References

  1. , , . Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg. 1958;7:561-73.
    [Google Scholar]
  2. , . Recent advances in diagnostic testing for viral infections. Biosci Horiz. 2016;9:1-11.
    [Google Scholar]
  3. , , , , , . ELISA for the detection of antibodies to Ebola viruses. J Infect Dis. 1999;179:192-8.
    [Google Scholar]
  4. , , , . Serological tests for the diagnosis of infectious diseases. BioChip J. 2016;10:346-53.
    [Google Scholar]
  5. , , , , , , . Evaluation of the performances of six commercial kits designed for dengue NS1 and anti-dengue IgM, IgG and IgA detection in urine and saliva clinical specimens. BMC Infect Dis. 2016;16:201.
    [Google Scholar]
  6. , , , , , , . Dengue specific immunoglobulin A antibody is present in urine and associated with disease severity. Sci Rep. 2016;6:272-98.
    [Google Scholar]
  7. , , , , , , . Value of routine dengue diagnostic tests in urine and saliva specimens. PLoS Negl Trop Dis. 2015;9:e0004100.
    [Google Scholar]
  8. , , , , , , . HIV-1 antibody serum negativity with urine positivity. Lancet. 1993;342:1458-9.
    [Google Scholar]
  9. , , , , . Testing for rubella-specific IgG antibody in urine. Pediatr Infect Dis J. 2000;19:104-9.
    [Google Scholar]
  10. , , , , , , . Application of commercial assays to detect IgG antibodies to hepatitis C virus in urine:A pilot study from autopsy cases. J Med Virol. 1994;44:187-91.
    [Google Scholar]
  11. , , , , . Evaluation of urine as a clinical specimen for diagnosis of hepatitis A. Clin Diagn Lab Immunol. 2002;9:840-5.
    [Google Scholar]
  12. , , , , . Anti-hepatitis A virus immunoglobulin M antibodies in urine samples for rapid diagnosis of outbreaks. Clin Diagn Lab Immunol. 2003;10:492-4.
    [Google Scholar]
  13. U.S. Food and Drug Administration. HIV-1. Available from: https://www.fda.gov/vaccines-blood-biologics/hiv-1
  14. , , , . Neutralizing antibody to polioviruses in normal human urine. J Clin Invest. 1962;41:805-15.
    [Google Scholar]
  15. , , . Induced latent infection of monkeys with vacuolating SV-40 Papova virus. Virus in kidneys and urine. Proc Soc Exp Biol Med. 1962;111:367-72.
    [Google Scholar]
  16. , , , , , . Experimental infection of rhesus with simian virus 40 (SV40) Proc Soc Exp Biol Med. 1969;130:196-203.
    [Google Scholar]
  17. , , , , , . Demonstration of IgA polio antibody in saliva, duodenal fluid and urine. Nature. 1967;214:420.
    [Google Scholar]
  18. , , . BK virus infection:An update on diagnosis and treatment. Nephrol Dial Transplant. 2015;30:209-17.
    [Google Scholar]
  19. , , , , . Occurrence of BK virus and BK virus-specific antibodies in the urine of patients receiving chemotherapy for malignancy. Infect Immun. 1975;11:1375-81.
    [Google Scholar]
  20. , . Simian virus 40, poliovirus vaccines, and human cancer:Research progress versus media and public interests. Bull World Health Organ. 2000;78:195-8.
    [Google Scholar]
  21. , , , , , , . Antibodies in urine of chimpanzees with chronic adenoviral viruria. Infect Immun. 1978;21:458-61.
    [Google Scholar]
  22. , , , . Comparison of serum, milk and urine as samples in an enzyme immunoassay for bovine leukaemia virus infection. Res Vet Sci. 1993;55:394-5.
    [Google Scholar]
  23. , , , , , , . Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. Int J Infect Dis. 2007;11:256-62.
    [Google Scholar]
  24. World Health Organization. Hepatitis A. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a
  25. , , , , . The detection in urine specimens of IgG and IgM antibodies to hepatitis A and hepatitis B core antigens. J Med Virol. 1992;38:265-70.
    [Google Scholar]
  26. World Health Organization. Hepatitis B. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
  27. World Health Organization. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
  28. , , , , , , . Antibodies to human immunodeficiency virus type 1 in the urine specimens of HIV-1-seropositive individuals. AIDS Res Hum Retroviruses. 1989;5:311-9.
    [Google Scholar]
  29. , , , , , . Detection of immunoglobulin G and A antibodies to rubella virus in urine and antibody responses to vaccine-induced infection. Clin Diagn Lab Immunol. 1998;5:24-7.
    [Google Scholar]
  30. , , , , . Hepatitis E virus infection. Clin Microbiol Rev. 2014;27:116-38.
    [Google Scholar]
  31. , , , , , . Hepatitis E antibody profiles in serum and urine. J Clin Lab Anal. 2000;16:137-42.
    [Google Scholar]
  32. , , , , , , . Human cytomegalovirus (HCMV)–revised. Transfus Med Hemother. 2010;37:365.
    [Google Scholar]
  33. , , . Detection of cytomegalovirus antigen and antibodies in the urine of small infants and children. J Med Virol. 1986;18:139-47.
    [Google Scholar]
  34. , , . Hantavirus nephropathy. J Am Soc Nephrol. 2008;19:1653-8.
    [Google Scholar]
  35. , , , , , , . Urine and free immunoglobulin light chains as analytes for serodiagnosis of Hantavirus infection. Viruses. 2019;11:809.
    [Google Scholar]
  36. World Health Organization. Influenza seasonal. Available from: https://www.who.int/ith/diseases/si_iAh1n1/en/
  37. , , . Diagnosis of respiratory virus infections using GACELISA of urinary antibodies. J Immunol Methods. 1996;195:73-80.
    [Google Scholar]
  38. World Health Organization. WHO strategy to pilot global respiratory syncytial virus surveillance based on the Global Influenza Surveillance and Response System (GISRS)... Available from: https://apps.who.int/iris/handle/10665/259853
  39. , , , , , , . Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome. Nat Commun. 20191943;10
    [Google Scholar]
  40. , , , , , , . First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. J Clin Virol. 2019;117:11-8.
    [Google Scholar]
  41. , , , , , , . Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine. J Med Virol. 2020;92:3774-83.
    [Google Scholar]
  42. , , , , , , . Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and western blot assays using serum, gingival-crevicular transudate, and urine samples. J Clin Microbiol. 1999;37:1100-6.
    [Google Scholar]
  43. , , , , , , . Detection of antibody IgG to HIV-1 in urine by sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) using recombinant proteins as antigens for diagnosis of HIV-1 infection. J Clin Lab Anal. 1993;7:353-64.
    [Google Scholar]
  44. , , , , , , . Immunoglobulin G antibody capture enzyme-linked immunosorbent assay:A versatile assay for detection of anti-human immunodeficiency virus type 1 and 2 antibodies in body fluids. J Clin Microbiol. 1992;30:3288-9.
    [Google Scholar]
  45. , , , , , , . Preliminary report:Accurate assays for anti-HIV in urine. Lancet. 1990;335:1366-9.
    [Google Scholar]
  46. , , , , . Stability of albumin, protein HC, immunoglobulin G, K-AND γ-chain immunoreactivity, orosomucoid and a 1-antitrypsin in urine stored at various conditions. Scand J Clin Lab Invest. 1994;54:199-206.
    [Google Scholar]
  47. , , . Non-invasive virological diagnosis:Are saliva and urine specimens adequate substitutes for blood? Rev Med Virol. 1991;1:73-8.
    [Google Scholar]
  48. , , , , , . The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006;7:R80.
    [Google Scholar]
  49. , , , , , , . Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteomics Clin Appl. 2009;3:1029-43.
    [Google Scholar]
  50. , , . Secretory γA in normal urine. J Clin Invest. 1968;47:1162-71.
    [Google Scholar]
  51. , , , , , . Size-selectivity of the glomerular barrier to high molecular weight proteins:Upper size limitations of shunt pathways. Kidney Int. 1998;53:709-15.
    [Google Scholar]
  52. , . What determines glomerular capillary permeability? J Clin Invest. 2004;114:1412-4.
    [Google Scholar]
  53. , . Quantitative studies of urinary immunoglobulins in hospital patients including patients with urinary tract infection. Clin Exp Immunol. 1970;6:189-96.
    [Google Scholar]
  54. , . Physicochemical and immunologic studies of gamma globulins of normal human urine. J Clin Invest. 1959;38:2159-67.
    [Google Scholar]
  55. , , , , , , . FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol. 2002;282:F358-65.
    [Google Scholar]
  56. , , , . The glomerular filtration barrier:Components and crosstalk. Int J Nephrol. 2012;2012:749010.
    [Google Scholar]
  57. , , , . Progression of glomerular diseases:Is the podocyte the culprit? Kidney Int. 1998;54:687-97.
    [Google Scholar]
  58. , , . Viruses and collapsing glomerulopathy:A brief critical review. Clin Kidney J. 2013;6:1-5.
    [Google Scholar]
  59. , , , , , , . Size and charge characteristics of the protein leak in dengue shock syndrome. J Infect Dis. 2004;190:810-8.
    [Google Scholar]
  60. , , , , , , . Significance of serum and urine antibodies in urinary tract infections in childhood. In: , , eds. Renal infection and renal scarring. London: Oxford University Press; . p. :117-32.
    [Google Scholar]
  61. , , , . Local synthesis of secretory IgA in experimental pyelonephritis. J Immunol. 1972;108:867-76.
    [Google Scholar]
  62. , , , , , . Local immune response in experimental pyelonephritis. J Clin Invest. 1968;47:2541-50.
    [Google Scholar]
  63. , . Lymphocyte sub-populations in the bladder wall in normal bladder, bacterial cystitis and interstitial cystitis. Br J Urol. 1994;73:508-15.
    [Google Scholar]
  64. , . Antibodies to HIV in urine. J Insur Med. 1989;21:210-2.
    [Google Scholar]
  65. , , , , , , . Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11:2079-87.
    [Google Scholar]
  66. , , , , . Evaluation of antigen and antibody detection in urine specimens from children with congenital human cytomegalovirus infection. J Med Virol. 1995;46:321-8.
    [Google Scholar]
  67. , , . The origin of urinary antibodies. J Hyg (Lond). 1953;51:245-57.
    [Google Scholar]
  68. , , . Viral nephropathy. Nat Clin Pract Nephr. 2006;2:254-62.
    [Google Scholar]
  69. , , . Viral nephropathies:Core curriculum 2008. Am J Kidney Dis. 2008;52:370-81.
    [Google Scholar]
  70. , , . Recent progress in HIV-associated nephropathy. J Am Soc Nephrol. 2002;13:2997-3004.
    [Google Scholar]
  71. , , . Immune complex renal disease and human immunodeficiency virus infection. Sem Nephrol. 2008;28:535-44.
    [Google Scholar]
  72. , , , . Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804-17.
    [Google Scholar]
  73. , . Hepatitis B and renal disease. Curr Hepat Rep. 2010;9:99-105.
    [Google Scholar]
  74. , . Viral-associated GN:Hepatitis B and other viral infections. Clin J Am Soc Nephrol. 2017;12:1529-33.
    [Google Scholar]
  75. , , , . Hepatitis C and kidney disease:A narrative review. J Adv Res. 2017;8:113-30.
    [Google Scholar]
  76. , , , , . Acute renal failure associated with nonfulminant acute viral hepatitis A. Indian J Nephrol. 2008;18:77-9.
    [Google Scholar]
  77. , , , , , , . Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol. 1999;10:1566-74.
    [Google Scholar]
  78. , , , , . Usefulness of enzyme immunoassay (EIA) for screening of anti HIV antibodies in urinary specimens:A comparative analysis. Med J Armed Forces India. 2014;70:211-4.
    [Google Scholar]
  79. , , , , , , . Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2. J Clin Microbiol. 1998;36:3657-61.
    [Google Scholar]
  80. , , , , , , . Human immunodeficiency virus:GACPAT and GACELISA as diagnostic tests for antibodies in urine. Trans R Soc Trop Med Hyg. 1993;87:181-3.
    [Google Scholar]
  81. , , , . Diagnostic detection of human immunodeficiency virus type-1 antibodies in urine, Jimma Hospital, south west Ethiopa. Ethiop Med J. 2006;44:363-8.
    [Google Scholar]
  82. , , , . Human immunodeficiency virus-1 antibody in urine. Indian J Nephrol. 2005;15:32-3.
    [Google Scholar]
  83. , . Urinary HIV-1 antibody patterns by western blot assay. Clin Lab Sci. 1998;11:336-8.
    [Google Scholar]
  84. , , , , . Detection of antibodies to hepatitis C virus in urine. Lancet. 1992;339:1607-8.
    [Google Scholar]
  85. , , , . Detection of immunoglobulin G antibodies to Helicobacter pylori in urine by an enzyme immunoassay method. J Clin Microbiol. 1993;31:2174-7.
    [Google Scholar]
  86. , , . Detection of anti-HIV in saliva and urine at the time of seroconversion. Clin Diagn Virol. 1994;1:299-311.
    [Google Scholar]
  87. , , , , , , . HCV antibodies in saliva and urine. J Med Virol. 1998;55:24-7.
    [Google Scholar]
  88. , , , , , , . Overcoming the effects of matrix interference in the measurement of urine protein analytes. Biomark Insights. 2012;7:1-8.
    [Google Scholar]
Show Sections
Scroll to Top